Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Next Previous
Trial Profile

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INCB 057643 (Primary) ; Ruxolitinib
  • Indications Chronic myelomonocytic leukaemia; Essential thrombocythaemia; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
  • Focus Adverse reactions
  • Acronyms LIMBER; LIMBER-103
  • Sponsors Incyte Corporation

Most Recent Events

  • 03 Jun 2025 According to an Incyte corporation media release, data from the study will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 -15, 2025, in Milan.
  • 30 Apr 2025 Results assessing INCB057643 mechanism of action including MK differentiation and biomarkers of inflammation and fibrosis in patient-derived mouse xenograft (PDX) model of myelofibrosis transplanted with patient cells from this study were presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 25 Apr 2025 According to an Incyte Corporation media release, Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25-30.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top